BLUE SAIL MEDICAL(SZ:002382) Xin Lang Cai Jing·2025-11-12 01:26Group 1 - The core viewpoint of the news is that 蓝帆医疗 (Blue Sail Medical) is experiencing fluctuations in its stock performance and financial metrics, with a notable increase in financing activities and a decline in revenue and profit [1][2]. Group 2 - On November 11, 蓝帆医疗's stock rose by 0.52%, with a trading volume of 53.85 million yuan. The financing buy-in amount for the day was 7.92 million yuan, while the financing repayment was 4.76 million yuan, resulting in a net financing buy-in of 3.16 million yuan [1]. - As of November 11, the total balance of margin trading for 蓝帆医疗 was 329 million yuan, with the financing balance accounting for 5.65% of the circulating market value, indicating a high level compared to the past year [1]. - The company reported a revenue of 4.18 billion yuan for the period from January to September 2025, representing a year-on-year decrease of 10.15%. The net profit attributable to the parent company was -286 million yuan, a decline of 30.09% year-on-year [2]. - 蓝帆医疗's main business revenue composition includes health protection products (70.08%), cardiovascular products (24.88%), emergency rescue products (3.72%), and others (1.32%) [1]. - As of October 20, the number of shareholders for 蓝帆医疗 was 74,800, an increase of 0.84% from the previous period, while the average circulating shares per person decreased by 0.84% to 13,362 shares [2]. - The company has distributed a total of 1.348 billion yuan in dividends since its A-share listing, with 403 million yuan distributed in the last three years [2].